Clinical trial
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are…
NCT05183646 · Dimerix Bioscience Pty Ltd, Industry · Recruiting
Key facts
| NCT number | NCT05183646 |
|---|---|
| Title | A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB |
| Official title | A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB) |
| Acronym | ACTION3 |
| Lead sponsor | Dimerix Bioscience Pty Ltd, Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | FSGS |
| Intervention type | Drug |
| Interventions | DMX-200, Placebo |
| Enrollment | 286 |
| Start date | May 30, 2022 |
| Primary completion | Dec 1, 2029 |
| Completion | Dec 1, 2029 |
| First posted | Jan 10, 2022 |
| Last update posted | Feb 3, 2026 |
| Countries | Argentina, Australia, Brazil, China, Czechia, Denmark, France, Germany, Hong Kong, Italy, Japan, Malaysia and 9 more |
At a glance
- 100–999 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: